Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating microRNAs in association with pancreatic cancer risk within 5 years

ABSTRACT: Circulating microRNAs in association with pancreatic cancer risk within 5 years

PROVIDER: PRJNA1090916 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Circulating microRNAs in association with pancreatic cancer risk within 5 years

Project description:miRNAs levels were measured in plasma samples of pancreatic cancer cases and controls collected within 5 years prior to diagnosis using the NanoString nCounter Human v3 miRNA expression panel

2024-04-01 | GSE262260 | GEO

Analysis of circulating microRNAs in adrenocortical tumours

Project description:Differential diagnosis of adrenocortical adenoma and carcinoma is of pivotal clinical relevance, as the prognosis and clinical management of benign and malignant adrenocortical tumours is entirely different. Circulating microRNAs are promising biomarker candidates of malignancy in several tumours. In the present study we investigate circulating microRNAs in adrenocortical tumours and to evaluate their potential applicability as biomarkers of malignancy.

2013-11-19 | GSE49674 | GEO

Circulating MicroRNAs as Biomarkers of Metabolic Syndrome

Project description:Circulating MicroRNAs as Biomarkers of Metabolic Syndrome

| PRJNA648409 | ENA

Analysis of circulating microRNAs in adrenocortical tumours

2013-11-19 | E-GEOD-49674 | biostudies-arrayexpress

Circulating MicroRNAs and Treatment Response in Childhood Asthma

Project description:Circulating MicroRNAs and Treatment Response in Childhood Asthma

| PRJNA556710 | ENA

Independent validation of circulating microRNAs as biomarkers in a case-control study of adolescents with type 1 diabetes for more than 8 years

Project description:MicroRNAs (miRNAs) are epigenetic regulators of gene activity. Analysis of circulating miRNAs enables minimal-invasive studies of disease mechanisms and identification of novel disease biomarkers. The aim of this case-control validation study was to investigate previously identified circulating miRNAs in Swedish adolescents with long-duration (8.0–16.5 years) type 1 diabetes (T1D), and healthy matched controls to confirm their utility as biomarker candidates to diagnose and monitor the progression of T1D. Quantitative PCR analysis of 23 previously reported miRNAs was performed in 24 T1D and 24 control individuals. Body composition was assessed by dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. Prospectively collected clinical data were retrieved from the Swedish diabetes quality registry. The selected miRNAs showed higher variability in both male and female T1D groups compared to controls. Statistical analysis confirmed differences for 12 miRNAs in comparison with controls, including miR-223-3p and miR-135a-5p, which previously were reported to be associated with T1D. MiR-34a-5p and miR-210-3p were positively associated with T1D duration and HbA1c (average from the last year), respectively. In conclusion, 12 previously reported miRNAs showed consistent differential expression between individuals with T1D and controls. Among these were miR-223-3p and miR-135a-5p, which are associated with cardiovascular/inflammatory disease and cancer, respectively.

2026-02-09 | GSE315292 | GEO

The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

Project description:MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy and in plasma samples taken after end of treatment. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.

2018-07-14 | GSE117063 | GEO

Circulating microRNAs in young individuals with long-duration type 1 diabetes in comparison with healthy controls

Project description:MicroRNAs (miRNAs) are short non-coding RNAs that are involved in post-transcriptional control of gene expression. The objective of this case-control study was to explore circulating miRNAs in young individuals with long-duration type 1 diabetes (T1D) and healthy controls. Twelve adolescents, age 15.0–17.9 years, with T1D duration of more than 8 years (mean 11.1 years), were enrolled from the Swedish diabetes quality registry. An age-matched control group (n = 12) was recruited. Circulating miRNAs (n = 187) were analyzed by quantitative PCR. We observed that 27 miRNAs were upregulated and one was downregulated in T1D. Six of these miRNAs were tissue-enriched (blood cells, gastrointestinal, nerve, and thyroid tissues). Six miRNAs with the largest difference in plasma, five up-regulated (hsa-miR-101-3p, hsa-miR-135a-5p, hsa-miR-143-3p, hsa-miR-223-3p and hsa-miR-410-3p (novel for T1D)) and one down-regulated (hsa-miR-495-3p), with P-values below 0.01, were selected for further in-silico analyses. AKT1, VEGFA and IGF-1 were identified as common targets. In conclusion, 28 of the investigated miRNAs were differently regulated in long-duration T1D in comparison with controls. Several associations with cancer were found for the six miRNAs with the largest difference in plasma. Circulating miRNAs are potential biomarkers and treatment targets with clinical implications for diabetes-related complications.

2023-10-18 | GSE226755 | GEO

Circulating microRNAs profile in patients with transthyretin variant amyloidosis

Project description:Circulating microRNAs profile in patients with transthyretin variant amyloidosis

| PRJNA629572 | ENA

Fingerprint of circulating microRNAs identify acute ischemic stroke patients

Project description:Fingerprint of circulating microRNAs identify acute ischemic stroke patients

| PRJNA1073466 | ENA